Yinuoke publication demonstrates a new orally delivered molecule that reverses cancer cachexia and increases survival using in vivo models
2024-02-13
临床结果
Yinuoke, a biopharmaceutical company pioneering breakthrough therapeutics for late-stage cancer patients announced today the publication of a manuscript in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle demonstrating the effectiveness of a new compound in alleviating cachexia and increasing the survival of tumor-bearing mice in a T-cell dependent manner.
Cancer cachexia, a devastating tumor-induced immune disorder leading to body wasting and reduced tolerability to therapeutics, occurs in 80% of all cancer patients and causes 25% of deaths. Previous attempts to treat cachexia have failed due to lack of efficacy in stabilizing patient weight and strength. Yinuoke treats cachexia as a tumor-driven autoimmune disorder rather than a metabolic condition. YNK105 reduces systemic inflammation without the toxic side effects caused by NSAIDS that limit its use. The data shows a significant improvement in cachexigenic tumor-bearing mice in overall survival, increases in body, fat, and muscle weight, and reductions in plasma IL-6 and tissue- derived Stat3. Most impressively, cachectic mice achieved a 100% survival rate with a combination treatment of YNK105 and chemotherapy.
“This research is the first demonstration that severe cachexia can be halted and reversed”, said Dr. Lingbing Zhang, founder and CEO of Yinuoke. “The ability to reverse cachexia expands the options for late-stage cancer patients to extend survival and live a higher quality of life. Reversing cachexia requires modulating the immune system’s inflammatory response for longer than an NSAID will allow. We identified R-ketorolac as a potential treatment for cachexia and now have significant evidence to support a superior efficacy and safety pro to current approaches using GDF-15 inhibitors or Anamorelin.”
“YNK105 has the potential to be a breakthrough treatment for cancer cachexia that I am excited to bring into the clinic,” said Dr. Andrew Hendifar of Cedars-Sinai. “Pancreatic cancer patients are highly susceptible to cachexia and treatment outcomes are severely impacted. Getting control of cachexia is critical for overall survival of patients with pancreatic cancer and especially for stage 4 and late diagnosed patients. These early studies support moving this program into clinical trials.”
The research appearing in the February 1st issue of the Journal of Cachexia, Sarcopenia and Muscle is led by Dr. Martina Schweiger and a team of scientists at the Institute of Molecular Biosciences, University of Graz, Austria.
About Yinuoke
Yinuoke is on a mission to save lives and conquer late-stage cancer through groundbreaking science and the development of first-in-class therapies where no options currently exist. Our vision is to revolutionize late-stage cancer by pushing boundaries and transforming it from a terminal disease to a manageable lifelong condition. Through innovative approaches and tailored treatments, we aim to empower patients with new possibilities for long-term remission and improved quality of life. For inquiries on partnering and investing please contact Suzanne Kennedy at skennedy@yinuokeus.com.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。